[Experience in treating psoriasis patients with the preparation Ditrastic].
The results of clinical trials of ditrastic, an agent manufactured by Orion, Finland, are analyzed. The drug contains 1.5 or 3% of ditranol. Of the 59 patients treated with this drug complete resolution of clinical eruptions was achieved in 43, the condition of 10 patients considerably improved, a partial effect was observed in 4, and no effect in 2 patients. Therefore ditrastic has proved to be a highly effective agent for the treatment of psoriasis, convenient for outpatient therapy.
Mashkilleĭson
A L
AL
Golousenko
I Iu
IIu
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000875:Anthralin / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004338:Drug Combinations / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010232:Paraffin / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy*; D013455:Sulfur / Q000627:therapeutic use*; D013997:Time Factors
D003879:Dermatologic Agents; D004338:Drug Combinations; C059206:ditrastic; D013455:Sulfur; D010232:Paraffin; D000875:Anthralin
Opyt lecheniia bol'nykh psoriazom preparatom "Ditrastik".